July 21, 2017 / 10:42 AM / a month ago

BUZZ-Aeterna Zentaris Inc: To explore strategic options

** Canadian drug developer's U.S.-listed shares up 15.7 pct at $3.24 premarket

** Says it has formed an independent "strategic review committee" to consider strategic and financing alternatives

** David Dodd has ceased to be CEO with immediate effect and will be replaced by Michael Ward, former chief compliance and legal officer at Sagent Pharmaceuticals - Aeterna Zentaris

** AEZS more than doubled on Wednesday, a day after U.S. FDA approved its treatment for adult growth hormone deficiency (AGHD), 2.5 yrs after rejecting its initial marketing application

** Up to Thursday's close, stock had fallen 22.2 pct YTD

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below